Travere Therapeutics, INC Form 4 insider transactions

Travere Therapeutics Director Roy D. Baynes reported a sale of 10,000 shares of common stock for $26.52 per share, executed under a Rule 10b5-1 trading plan.

Travere Therapeutics CEO Eric M. Dube reported the sale of 85,000 shares of common stock, acquired through stock options, under a pre-arranged trading plan.

Elizabeth E. Reed, Chief Legal Officer of Travere Therapeutics, sold 10,000 shares of common stock on April 1, 2026, as part of a pre-arranged 10b5-1 trading plan.

Travere Therapeutics' Chief Legal Officer, Elizabeth E. Reed, exercised options and sold 10,000 shares of common stock for a profit, pursuant to a pre-arranged 10b5-1 plan.

Travere Therapeutics CEO Eric Dube exercised stock options and sold 60,000 common shares for a profit, as per a pre-arranged 10b5-1 plan.

Travere Therapeutics' Chief Legal Officer, Elizabeth E. Reed, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 plan.

Travere Therapeutics' Chief Medical Officer, Jula Inrig, sold common stock on February 4, 2026, under a pre-arranged 10b5-1 plan, including shares to cover tax obligations from vested restricted stock units.

Travere Therapeutics' CFO, Christopher R. Cline, sold common stock totaling 1,745 shares on February 4, 2026, under a pre-arranged 10b5-1 plan.

Travere Therapeutics' Chief Legal Officer, Elizabeth E. Reed, sold common stock totaling 2,994 shares on February 4, 2026, under a pre-arranged 10b5-1 plan.

Travere Therapeutics CEO Eric Dube reported the acquisition of restricted stock units and stock options, alongside sales of common stock to cover tax obligations.

Travere Therapeutics' Chief Medical Officer, Jula Inrig, reported the acquisition of restricted stock units and stock options, alongside a tax-related sale of common stock.

Travere Therapeutics' CFO, Christopher R. Cline, reported the acquisition of common stock and stock options, alongside a tax-related 'sell to cover' transaction.

Travere Therapeutics' Chief Commercial Officer, Peter Heerma, reported the acquisition of restricted stock units and stock options, alongside a 'sell to cover' transaction for tax obligations.

Travere Therapeutics' Chief Research Officer, William E. Rote, reported the acquisition of restricted stock units and stock options, alongside a sale of common stock to cover tax obligations.

Travere Therapeutics' SVP, Chief Accounting Officer, Sandra Calvin, reported the acquisition of restricted stock units and stock options, alongside a tax-related stock sale.

Travere Therapeutics' Chief Legal Officer, Elizabeth E. Reed, reported the acquisition of restricted stock units and stock options, alongside a mandated 'sell to cover' transaction for tax obligations.

Travere Therapeutics CEO Eric M. Dube exercised 60,000 stock options and sold the resulting shares under a pre-arranged 10b5-1 plan.

Elizabeth E. Reed, Travere Therapeutics' Chief Legal Officer, exercised stock options and sold 10,000 shares under a pre-arranged plan.

Travere Therapeutics' Chief Medical Officer, Jula Inrig, sold common stock to cover tax withholding obligations related to vested restricted stock units, with one transaction also part of a pre-arranged 10b5-1 plan.

Travere Therapeutics' Chief Commercial Officer, Peter Heerma, sold 4,980 shares of common stock at $40 per share under a pre-arranged 10b5-1 plan.

Travere Therapeutics' Chief Research Officer, William E. Rote, exercised stock options and subsequently sold 60,000 shares of common stock for a profit, as detailed in a recent SEC Form 4 filing.

Travere Therapeutics' Chief Medical Officer, Jula Inrig, exercised stock options and subsequently sold 15,000 shares of common stock.

Travere Therapeutics' SVP, Chief Accounting Officer Sandra Calvin sold 7,402 shares of common stock for $40 per share, reducing her direct beneficial ownership to 38,233 shares.

Travere Therapeutics' SVP, Chief Accounting Officer, Sandra Calvin, sold 2,910 shares of common stock for $36 per share under a pre-arranged trading plan.

Travere Therapeutics' CFO, Christopher R. Cline, exercised stock options and sold 20,000 shares of common stock under a pre-arranged 10b5-1 plan.

Travere Therapeutics' SVP, Chief Accounting Officer, Sandra Calvin, sold 67,115 shares of common stock at $36.00 after exercising various stock options.

Travere Therapeutics Director Timothy Coughlin exercised stock options and subsequently sold 18,000 shares of common stock for a profit.

Travere Therapeutics' Chief Commercial Officer, Peter Heerma, reported the sale of 5,591 shares and a charitable gift of 1,078 shares of common stock.

Travere Therapeutics CEO Eric Dube exercised stock options and subsequently sold 129,999 shares of common stock in late October 2025 under a pre-arranged trading plan.

Peter Heerma, Chief Commercial Officer of Travere Therapeutics, Inc., sold 2,662 shares of common stock at $30 per share pursuant to a pre-arranged 10b5-1 plan.